Clinical ResearchCharacteristics and In-Hospital Outcomes of Patients With Non–ST-Segment Elevation Myocardial Infarction and Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention
Key Words
Abbreviations and Acronyms
Cited by (0)
Dr. Roe has received research funding and has been a consultant and member of the Speakers' Bureaus for the companies that fund the ACTION registry via the American College of Cardiology—Bristol-Myers Squibb/sanofi aventis and Schering-Plough; has received research funding from Eli Lilly, Roche, Bristol-Myers Squibb, American College of Cardiology, and the American Heart Association; and consulting fees or honoraria from KAI Pharmaceuticals, Bristol-Myers Squibb, Sanofi Aventis, Merck, Orexigen, Holsinn Pharmaceuticals, AstraZeneca, and Regeneron. Dr. Wiviott has been a consultant to sanofi-aventis, Bristol-Myers Squibb, and AstraZeneca; has received research support and/or honoraria from Eli Lilly, Daiichi Sankyo, AstraZeneca, Schering-Plough, Merck, and Pfizer Inc.; and does CME speaking for Eli Lilly, AstraZeneca, and Daiichi Sankyo. Dr. Saucedo has been a consultant to Eli Lilly, Bristol-Myers Squibb/sanofi-aventis, and The Medicines Company; and has received research support and/or honoraria from Schering-Plough, Pfizer Inc., Merck, Eli Lilly, Abbott, Boston Scientific, and Medtronic. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.